In Reply We thank Chien and colleagues for their interest in our study of aspirin use and incident hepatocellular carcinoma (HCC) in the Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS) cohorts.1 The authors argue that a disproportionate number of the patients with HCC were women; however, the number of cases reflects our underlying population, which was composed of 87 507 women (Nurses’ Health Study) and 45 864 men (Health Professionals Follow-up Study). Indeed, our sex-specific cumulative incidence of HCC was 2 per 100 000 women and 5 per 100 000 men, which corresponds to population-based estimates for the time period of our study (1980-2012 in women; 1986-2012 in men).2
Simon TG, Chan AT. Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin—In Reply. JAMA Oncol. Published online May 02, 20195(6):911–912. doi:10.1001/jamaoncol.2019.0630
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: